Instead, PD animal models that induce gradual, chronic cell loss via direct alpha-synuclein injections to the midbrain or mutations to PD-relevant genes, would be ideal for assessing whether specific psychedelics can slow or reverse pathological progression (Buhidma et al., 2020). Here, SNCA is linked to Parkinson disease.